U.S. Markets close in 5 mins.

Karyopharm Therapeutics Inc. (KPTI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.18-0.24 (-2.85%)
As of 3:55PM EDT. Market open.
People also watch
EPZMMGNXXLRNOMEDPTCT

Karyopharm Therapeutics Inc.

85 Wells Avenue
2nd Floor
Newton, MA 02459
United States
617-658-0600
http://www.karyopharm.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees108

Key Executives

NameTitlePayExercisedAge
Dr. Michael G. Kauffman M.D., Ph.D.Co-Founder, Chief Exec. Officer and Director773.46kN/A54
Dr. Sharon Shacham Ph.D., M.B.A.Co-Founder, Co-Chairman of Scientific Advisory Board, Pres and Chief Scientific Officer592.26kN/A47
Mr. Justin A. Renz CPA, MST, MBAAdvisor485.36kN/A45
Dr. Mansoor Raza Mirza M.D.Clinical Consultant, Director and Member of Scientific Advisory Board254.38kN/A56
Mr. Michael J. Todisco CPAActing Principal Financial and Accounting OfficerN/AN/A52
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Corporate Governance

Karyopharm Therapeutics Inc.’s ISS Governance QualityScore as of August 1, 2017 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.